This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
of Humira revenues to biosimilar competition.
Mylan and Biocon have launched their biosimilar Herceptin (trastuzumab) under the brand name Ogivri, after Roche tried and failed to get an injunction on sales of biosimilars in the US. . ... Alongside Herceptin, this includes Avastin (bevacizumab) and
However, both Roche and Alexion could face competition from biosimilars, as Amgen recently filed a patent infringement action against Soliris. ... Amgen has interest in the therapy area due to a biosimilar version of Soliris that it has advanced into
That initial finding damaged AbbVie’s hopes of growing sales of Rinvoq to offset the anticipated loss of Humira revenues to biosimilar competitors when it loses its patent exclusivity.
Otezla slots into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already available
Otezla slots nicely into Amgen’s existing psoriasis and anti-inflammatory portfolio, which includes TNF inhibitor Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s top-selling TNF blocker Humira (adalimumab).
More from news
Approximately 136 fully matching, plus 336 partially matching documents found.
Biosimilar fail. Another stumbling block has been our over-reliance on market-based solutions to this problem, ie, generics. ... The thinking was at that time we’d solved the biosimilar problem, and here we are nine years later saying, no, we haven’t.
Switching from an originator biologic to a cheaper biosimilar. These are all examples of the kind of treatment transitions patients experience that can be supported by Patient Support Programmes.
Whether we market branded products that offer no real superiority over generics, biosimilars or me-toos or we sell innovative products whose price differential is not financially justified, much of what
It will compete with numerous treatment modalities, including entrenched biological agents and biosimilar biologicals.
The world’s biggest selling drug, Humira, lost its market exclusivity in Europe to biosimilar competition in 2018, and AbbVie is well aware of the impending US patent expiry in 2022. ... Finally, 2019 will see a rapid increase in the uptake of Humira
More from intelligence
Approximately 11 fully matching, plus 57 partially matching documents found.
and biosimilar specialists,” he added.
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
More from appointments
Approximately 1 fully matching, plus 15 partially matching documents found.
Conclusions. Pharmaceutical tendering will stay as a key procurement approach for pharmaceutical products, especially for hospital products but also in outpatient settings for generics/biosimilars or other segments of products with
In the past year, the competition in biosimilars and complex generics has complicated the launch landscape.
Specifically, it has focused its efforts on increasing competition in biosimilars and complex generics, which are difficult to copy, in a bid to increase competition and drive down prices.
In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. Eli Lilly responded by launching an LOE strategy that tapped into patients’ desire for a stable treatment plan.
in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... Uptake curve of JAKS compared to other new entrants and biosimilars.
More from PMHub
Approximately 13 fully matching, plus 26 partially matching documents found.
At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...